The case for treating mild hyperthyroidism

Article

Ob/gyns are increasingly being called upon to manage subclinical thyroid disease. In this concluding article of a two-part series, two experts clarify the controversy over when to treat mild hyperthyroidism. Do treat a mildly overactive thyroid in elderly patients, they say, because low bone density and cardiac abnormalities can do substantial harm.

Few colleagues would argue over how to diagnose or treat overt thyroid disease. But it's a different story for more subtle "mild" thyroid disease-a term now commonly preferred to "subclinical."1 A key point from our article on mild hypothyroidism ("When should you screen for and treat mild hypothyroidism?" Contemporary OB/GYN, January 2006) http://www.contemporaryobgyn.net/obgyn/article/articleDetail.jsp?id=283482 holds true for mild hyperthyroidism: Diagnosing and deciding when to treat mild thyroid disease is still complicated by controversies over the reference values of the thyroid function tests upon which we base the diagnosis of disease and many clinical decisions. Once again our goal here is to discuss factors affecting your decision on when to treat mild hyperthyroidism and to give causes, guidelines, and treatment options.

Measuring 'normal' thyroid function

Also as discussed in Part I, when individuals with risk factors for autoimmune thyroid disease (especially thyroid antibodies), were excluded from a large control population, the average TSH was ~1.5 μU/mL.2 The lower limit for TSH in this group, and in other reports, was ~0.4 μU/mL. [Hence, mild hyperthyroidism may be defined by a TSH below 0.4 μU/mL with normal thyroid hormone levels (free T4 and T3). However, patients with mild hyperthyroidism are often divided further into two subgroups, one with a TSH of 0.1 to 0.4, and a second group with TSH under 0.1. With third-generation TSH assays, TSH may be reported at levels below 0.1, and this clearly indicates hyperthyroidism.]

Recent Videos
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
Lauren Streicher, MD
© 2024 MJH Life Sciences

All rights reserved.